1. Home
  2. SF vs RGEN Comparison

SF vs RGEN Comparison

Compare SF & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stifel Financial Corporation

SF

Stifel Financial Corporation

SELL

Current Price

$67.43

Market Cap

10.6B

Sector

Finance

ML Signal

SELL

Logo Repligen Corporation

RGEN

Repligen Corporation

SELL

Current Price

$175.48

Market Cap

11.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SF
RGEN
Founded
1890
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6B
11.0B
IPO Year
1994
1995

Fundamental Metrics

Financial Performance
Metric
SF
RGEN
Price
$67.43
$175.48
Analyst Decision
Buy
Buy
Analyst Count
8
22
Target Price
$84.50
★ $197.95
AVG Volume (30 Days)
★ 1.3M
1.2M
Earning Date
10-21-2026
10-27-2026
Dividend Yield
★ 1.98%
N/A
EPS Growth
N/A
★ 286.96
EPS
★ 2.83
0.24
Revenue
★ $6,347,533,000.00
$141,236,000.00
Revenue This Year
$8.99
$12.87
Revenue Next Year
$8.65
$29.67
P/E Ratio
★ $24.25
$767.71
Revenue Growth
6.65
★ 35.10
52 Week Low
$66.89
$100.99
52 Week High
$134.74
$198.87

Technical Indicators

Market Signals
Indicator
SF
RGEN
Relative Strength Index (RSI) 25.78 47.86
Support Level N/A $158.62
Resistance Level $74.68 $174.87
Average True Range (ATR) 1.55 9.22
MACD 0.06 -0.93
Stochastic Oscillator 10.00 42.29

Price Performance

Historical Comparison
SF
RGEN

About SF Stifel Financial Corporation

Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a Saint Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: